Amarin (AMRN) Sees Upside After AstraZeneca Scoops-Up Omthera (OMTH)

May 28, 2013 7:42 AM EDT
Amarin Corp Plc (NASDAQ: AMRN) is seeing pre-open interest Tuesday after AstraZeneca (NYSE: AZN) acquired fellow fish oil pharmaceutical company Omthera Pharmaceuticals (NASDAQ: OMTH) for as much as $443 million.

While the comparable valuation of the deal is not viewed as positive for Amarin, speculators suggest the deal activity puts the spotlight directly on Amarin.

Shares of Amarin last traded at $7.05, up 4 percent.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Rumors, Trader Talk